Overview

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Status:
Completed
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.
Phase:
Early Phase 1
Details
Lead Sponsor:
Carol Fabian, MD
Collaborator:
DSM Nutritional Products, Inc.